State Street Corp. Updates Passive Stake in Arcutis Bio
Ticker: ARQT · Form: SC 13G/A · Filed: Jan 23, 2024 · CIK: 1787306
| Field | Detail |
|---|---|
| Company | Arcutis Biotherapeutics, Inc. (ARQT) |
| Form Type | SC 13G/A |
| Filed Date | Jan 23, 2024 |
| Risk Level | low |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: institutional-ownership, amendment, passive-investment
TL;DR
**State Street still owns Arcutis Bio shares, signaling continued institutional interest.**
AI Summary
State Street Corporation filed an amended SC 13G/A on January 23, 2024, indicating its ownership of Arcutis Biotherapeutics, Inc. common stock as of December 31, 2023. This filing is an update to a previous disclosure, confirming State Street's continued passive investment in the pharmaceutical company. For investors, this means a major institutional investor maintains a position, which can signal confidence, but the specific percentage of ownership is not detailed in the provided excerpt.
Why It Matters
This filing confirms a significant institutional investor, State Street Corporation, continues to hold shares in Arcutis Biotherapeutics, Inc., which can be a positive signal for current and prospective shareholders.
Risk Assessment
Risk Level: low — This is a routine update from a passive institutional investor and does not indicate any immediate risk or significant change in company fundamentals.
Analyst Insight
Investors should note that State Street Corporation, a major institutional investor, continues to hold a passive stake in Arcutis Biotherapeutics, Inc. This is a routine update and doesn't suggest an immediate need for action, but it confirms ongoing institutional interest. Further research into the specific percentage of ownership and any changes from previous filings would provide more actionable insight.
Key Players & Entities
- State Street Corporation (company) — the reporting person filing the SC 13G/A
- Arcutis Biotherapeutics, Inc. (company) — the subject company whose securities are being reported
- December 31, 2023 (date) — the date of the event requiring the filing
- 03969K108 (other) — CUSIP number for Arcutis Biotherapeutics, Inc. common stock
FAQ
What type of filing is this document?
This document is an SC 13G/A, which is an amendment to a Schedule 13G filing, indicating a change or update to a previously reported beneficial ownership of securities.
Who is the 'Reporting Person' in this filing?
The 'Reporting Person' is STATE STREET CORPORATION, identified by CIK 0000093751.
What is the 'Subject Company' whose securities are being reported?
The 'Subject Company' is Arcutis Biotherapeutics, Inc., identified by CIK 0001787306.
What was the 'Date of Event Which Requires Filing of This Statement'?
The 'Date of Event Which Requires Filing of This Statement' was December 31, 2023.
Under which rule is this Schedule 13G/A filed?
This Schedule 13G/A is filed under Rule 13D-1 (B), as indicated by the 'X' in the appropriate box.
Filing Details
This Form SC 13G/A (Form SC 13G/A) was filed with the SEC on January 23, 2024 regarding Arcutis Biotherapeutics, Inc. (ARQT).